Pain Therapeutics Can't Duck Investors' Remoxy Suit

Law360, New York (November 20, 2012, 6:17 PM EST) -- A Texas federal judge refused Tuesday to derail a putative class action accusing Pain Therapeutics Inc. of misleading investors about the prospects for painkiller Remoxy, saying there was plausible evidence executives might have concealed damaging information about the drug.

U.S. District Judge Sam Sparks, who two months ago dismissed the lawsuit because it lacked specifics, preserved an amended complaint after finding sufficient reason to believe the company’s top brass touted the oxycodone treatment despite knowing the U.S. Food and Drug Administration was unimpressed with its performance....
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

KB Partners I, LP et al v. Barbier et al


Case Number

1:11-cv-01034

Court

Texas Western

Nature of Suit

Securities/Commodities

Judge

Sam Sparks

Date Filed

December 2, 2011

Law Firms

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.